Source: Clinical Trials Arena

AptaTargets: aptaTargets initiates dosing with ApTOLL in Phase Ib Covid-19 trial

Analysing the safety and efficacy of ApTOLL in hospitalised Covid-19 patients is the aim of the trial. The post aptaTargets initiates dosing with ApTOLL in Phase Ib Covid-19 trial appeared first on Clinical Trials Arena.

Read full article »
AptaTargets's Competitors | AptaTargets's News | AptaTargets's Financials
Stay up-to-date with the latest news on AptaTargets
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
David Segarra's photo - Co-Founder & CEO of AptaTargets

Co-Founder & CEO

David Segarra

CEO Approval Rating

70/100

Read more
Stay up-to-date with the latest news on AptaTargets